Transdermal Estrogen
Estrogen delivered through the skin via patch, gel, or cream, bypassing first-pass hepatic metabolism. Unlike oral estrogen, which passes through the liver before reaching systemic circulation, transdermal delivery provides steady-state estrogen levels with significantly lower impact on coagulation factors, C-reactive protein, and triglycerides. This pharmacokinetic difference is clinically important for women with thrombophilic risk factors or metabolic concerns.
In RRM practice, transdermal estrogen is used primarily for premature ovarian insufficiency and in selected perimenopausal management protocols. For women with POI, hormone replacement is not optional wellness support. It is medical necessity. Estrogen deficiency at age 28 or 34 carries cardiovascular, skeletal, and neurological consequences that accumulate silently without treatment. The goal is physiological replacement, not supraphysiologic dosing.
Transdermal delivery allows more precise titration than oral preparations and avoids the hepatic triglyceride stimulation associated with oral estrogen. Combined with progesterone support (typically micronized progesterone or a progestin), transdermal regimens can be tailored to the individual's hormonal profile, symptoms, and cycle remnants in women with partial ovarian function.
The distinction between transdermal estrogen as physiological replacement and suppressive medications is fundamental to RRM framing. Physiological replacement restores what the body cannot produce. Suppressive medications override what the body is producing. These are different pharmacological goals requiring different clinical conversations.
This content is for educational purposes only and does not constitute medical advice. Consult an RRM clinician or healthcare provider for guidance specific to your situation.